USPTO serial 88325215
GLIMMUNE THERAPEUTICS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- REEVES, APRIL ELIZABETH
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with GLIMMUNE THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Skin soaps; SHAMPOOS; SUNSCREEN FOR COSMETIC USE; PERFUMERY; ESSENTIAL OILS; BODY POWDER; COSMETICS; ANTI-AGING CREAMS; HAIR LOTION; SKIN CREAMS; SKIN moisturizing GELS; non-medicated soaps for face; moisturizing body lotions; NON-MEDICATED MOUTHWASHES | ACTIVE | — |
| 005 | Pharmaceutical preparations for human use for the treatment of respiratory disorders; nasal spray preparations; Opium alkaloid preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical antitussive-cold preparations; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for skin care; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for wounds; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, anticoagulants; pharmaceutical products and preparations against dry skin caused by pregnancy; pharmaceutical products and preparations for chloasma; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products for ophthalmological use; pharmaceutical products for skin care for animals; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of joint disease; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical skin lotions; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals, namely, anti-infectives; pharmaceuticals, namely, antihelmintics; pharmaceuticals, namely, inducers of erections; pharmaceuticals, namely, lipid lowering agents; preparation for the relief of pain; preparations for the treatment of asthma | ACTIVE | — |
| 010 | SPIROMETER; INHALERS for therapeutic use; NEBULIZERS for medical purposes; DIAGNOSTIC APPARATUS FOR MEDICAL PURPOSES, namely, medical diagnostic apparatus for testing DNA and RNA samples | ACTIVE | — |
| 041 | Educational services, namely, providing workshops and seminars in the fields of cancer treatment, oncology, immunology and pain management; publication of journals featuring the results of clinical trials for pharmaceutical preparations; Education services, namely, conducting online instruction and courses in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments; provision of educational content, namely, providing on-line instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments; training in the use and operation of medical devices, medical imaging apparatus and medical research apparatus and consultation relating thereto; educational services, namely, conducting live and online seminars, classes, workshops, lectures, panel discussions, and training programs in the field of pharmaceutical products, healthcare and medical diseases, disorders and related treatments; educational services, namely, providing non-downloadable webinars in the field of health and medical information and distribution of course material in connection therewith; education services, namely, developing, arranging and conducting educational programs and providing courses of instruction in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine; providing training programs and developing training programs relating to the use and operation of medical devices, medical research apparatus and consultation relating thereto; providing online publications, namely, instructional materials in the field of pharmaceutical products, healthcare and medical disease, disorders and related treatments; conducting educational seminars in the fields of healthcare, the use of pharmaceuticals, and medical devices, medical research, surgery, medical science and medicine | ACTIVE | — |
| 042 | Scientific research for medical purposes; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Scientific and technological services, namely, scientific research, analysis, testing in the field of oncology, immunology and pain management; Medical research in the fields of oncology, immunology and pain management; clinical research in the fields of oncology, immunology and pain management; scientific research and development; pharmaceutical drug development services; pharmaceutical research and development; research and development for new products for others; Scientific and technological services, namely, scientific research and analysis in the field of chemicals, pharmaceutical preparations, dietetic preparations, demo-cosmetic preparations, and biotechnology; design and testing for new product development; Medical research, namely, diagnostic testing and analysis for industrial purposes; scientific research in the fields of chemistry, biotechnology and pharmacology; MEDICAL AND PHARMACEUTICAL RESEARCH SERVICES; SCIENTIFIC RESEARCH SERVICES FOR MEDICAL PURPOSES INCLUDING AND NOT LIMITED TO BACTERIOLOGICAL RESEARCH SERVICES; BIOMEDICAL RESEARCH SERVICES; LABORATORY RESEARCH SERVICES in the field of cancer treatment, oncology, immunology and pain management; conducting clinical trials for others; Scientific research in the field of pharmacology; medical research services conducted in a laboratory; Scientific and technological services, particularly scientific research and analysis, in the fields of medicine, health, fitness, exercise and wellness | ACTIVE | — |
| 044 | PROVIDING INFORMATION IN THE FIELD OF MEDICINE AND HEALTH; MEDICAL SERVICES; MEDICAL ASSISTANCE; HYGIENE CARE FOR HUMAN BEINGS; MEDICAL CLINIC SERVICES; disseminating medical information to patients for better lifestyle management to handle the treatment of side effects in the course of treatment of cancer, pain management, skin care, management of diabetes, management of asthma, Chronic Obstructive Pulmonary Disease (COPD) and respiratory diseases | ACTIVE | — |
| 045 | Licensing of patents, trademarks and intellectual property | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Glenmark Pharmaceuticals Limited
- Other trademarks owned by Glenmark Pharmaceuticals Limited
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named GLIMMUNE THERAPEUTICS
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 19, 2021 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 19, 2021 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 15, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 21, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 21, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 1, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 18, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 18, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 18, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 18, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 18, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 6, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 6, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 6, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 13, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 13, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 13, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 20, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 20, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 20, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 13, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 22, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 7, 2019 | NWAP | NEW APPLICATION ENTERED | — |